Opus Genetics AAQS

Mitä Opus Genetics tekee? Ocuphire Pharma, Inc. is a health care company based in Farmington Hills, Michigan, specializing in the research and development of ophthalmic biopharmaceuticals. Listed on the market on 30 November 2004, the firm focuses on therapies for refractive and retinal eye disorders. Its pipeline features Nyxol Eye Drops, a once-daily formulation of phentolamine mesylate aimed at reducing pupil diameter and improving visual acuity for conditions such as presbyopia and night vision disturbances. Additionally, the company develops APX3330, an oral tablet targeting retinal and choroidal diseases, alongside in-licensed second-generation candidates APX2009 and APX2014. The organization employs a small team dedicated to advancing these innovative treatments. Opus Genetics on yksi Eurpooliin suosituimmista yhtiöistä.